Phase II Trial Irinotecan and Cisplatin Induction Chemotherapy Followed by Radiotherapy Concurrently With Etoposide/Cisplatin in Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer
- To evaluate the efficacy of induction chemotherapy comprising irinotecan hydrochloride
and cisplatin in patients with locally advanced, unresectable stage III non-small cell
- To evaluate the feasibility of radiotherapy administered concurrently with etoposide
and cisplatin chemotherapy after induction chemotherapy in these patients.
- To evaluate the toxicity of induction chemotherapy comprising irinotecan hydrochloride
and cisplatin in these patients.
- To assess whether this induction chemotherapy regimen will improve patient survival
when compared with outcomes from the predecessor study, SWOG-9019.
OUTLINE: Patients receive dose-dense induction chemotherapy comprising irinotecan
hydrochloride IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to
After completion of induction chemotherapy, patients undergo radiotherapy five days a week
for approximately 7 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV
on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and 29-33.
After completion of study therapy, patients are followed at 6 weeks.
Masking: Open Label, Primary Purpose: Treatment
Rate of local/regional control
Joo-Hang Kim, MD